, Volume 8, Issue 6, pp 405–407 | Cite as

Current Status of Immunotherapy

  • Alan Coates
Guest Editorials


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Klein, G.: Tumour specific transplantation antigens. Cancer Research 28: 625 (1968).PubMedGoogle Scholar
  2. 2.
    Röllinghoff, M.; Rouse, B.T. and Warner, N.L.: Tumour immunity to murine plasma cell tumours. I. Tumour associated transplantation antigens of NZB and BALB/c plasma cell tumours. Journal of the National Cancer Institute 50: 159(1973).PubMedGoogle Scholar
  3. 3.
    Hellström, K.E. and Hellström, I.: Lymphocyte mediated cytotoxicity and blocking serum activity to tumour antigens. Advances in Immunology 18: 209(1974).PubMedCrossRefGoogle Scholar
  4. 4.
    Burnet, F.M.: Implications of cancer immunity. Australian and New Zealand Journal of Medicine 1: 71(1973).CrossRefGoogle Scholar
  5. 5.
    Mathé, G.; Pouillart, P. and Lapeyraque, F.: Active immunotherapy of L1210 leukaemia applied after the graft of tumour cells. British Journal of Cancer 23: 814 (1969).PubMedCrossRefGoogle Scholar
  6. 6.
    Baldwin, R.W. and Pimm, M.V.: BCG immunotherapy of a rat sarcoma. British Journal of Cancer 25:281(1973).CrossRefGoogle Scholar
  7. 7.
    Currie, G.A.: Eighty years of immunotherapy: a review of immunological methods used for the treatment of human cancer. British Journal of Cancer 26: 141(1972).PubMedCrossRefGoogle Scholar
  8. 8.
    Mathé, G.; Amiel, J.L.; Schwarzenberg, L; Schneider, M.; Cattan, A.; Schlumberger, J.R.; Hayat, M. and De Vassal, F: Active immunotherapy for acute lymphoid leukemia. Lancet 7: 697 (1969).CrossRefGoogle Scholar
  9. 9.
    Powles, R.L.; Crowther, D.; Bateman, C.J.T.; Beard, M.E.J.; McElwain, T.J.; Russell, J.; Lister, T.A.; Whitehouse, J.M.A.; Wrigley, P.F.H.; Pike, M.; Alexander, P. and Hamilton Fairley, G.: Immunotherapy for acute myelogenous leukaemia. British Journal of Cancer 28: 365(1973).PubMedCrossRefGoogle Scholar
  10. 10.
    Vogler, W.R. and Chan, Y.K.: Effect of Bacillus-Calmette Guerin (BCG) in prolongation of remissions in acute myeloblastic leukemia (AML). Proceedings of the American Association for Cancer Research 75: 164(1974) (Abstract No. 723).Google Scholar
  11. 11.
    Gutterman, J.U.; McBride, C.; Freireich, E.J.; Mavligit, G.; Frei, E.III and Hersh, EM: Active immunotherapy with BCG for recurrent malignant melanoma. Lancet 1: 1208 (1973).PubMedCrossRefGoogle Scholar
  12. 12.
    Sokal, J.E.; Aungst, C.W. and Synderman, M.: Prolongation of remission in stage I and II lymphoma by BCG vaccination. Proceedings of the American Association for Cancer Research 75: 13 (1973) (Abstract No. 51).Google Scholar

Copyright information

© Adis Press 1974

Authors and Affiliations

  • Alan Coates
    • 1
  1. 1.Clinical Research Unit, Walter and Eliza Hall Institute of Medical ResearchRoyal Melbourne HospitalMelbourneAustralia

Personalised recommendations